Evidence map›Paper›PMID 26687301›Full record

ArticleScientific reports2015

Using aptamers to elucidate esophageal cancer clinical samples.

Zhenxu Liu, Yi Lu, Ying Pu, Jun Liu, Bo Liu, Bo Yu, Ke Chen, Ting Fu, Chaoyong James Yang, Huixia Liu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Next RNA Therapeutics: The Mine of Non-Coding.International journal of molecular sciences · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Zhenxu LiuXiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Yi LuXiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Ying PuXiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Jun LiuXiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Bo LiuXiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Bo YuXiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Ke ChenXiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Ting FuMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, Hunan 410082, China.
Chaoyong James YangState Key Laboratory for Physical Chemistry of Solid Surfaces, Key Laboratory for Chemical Biology of Fujian Province, Key Laboratory of Analytical Chemistry, and Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, China.
Huixia LiuXiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Weihong TanMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, Hunan 410082, China.
Central South University · CNHunan University · CNXiamen University · CNXiangya Hospital Central South University · CN

Funding

Development of molecular probes for biomedical applicationsR01GM079359 · NIGMS · UNIVERSITY OF FLORIDA · PI TAN, WEIHONG · 2007 to 2016
$2.3M
Molecular Target for Liver Cancer Diagnosis and TherapyR01CA133086 · NCI · UNIVERSITY OF FLORIDA · PI LIU, CHEN · 2009 to 2013
$1.5M
Expanded DNA, In Vitro Selection, Aptamers, and CancerR01GM111386 · NIGMS · FOUNDATION FOR APPLIED MOLECULAR EVOLUTN · PI BENNER, STEVEN A · 2014 to 2016
$1.2M
NCI NIH HHS CA133086NCI NIH HHS R01 CA133086NIGMS NIH HHS GM079359NIGMS NIH HHS GM111386NIGMS NIH HHS R01 GM079359NIGMS NIH HHS R01 GM111386
6 · The paper itself

Abstract

The epithelial cell adhesion molecule (EpCAM) is closely correlated with the occurrence and development of various cancers of epithelial origin. This study tested, for the first time, the ability of EpCAM aptamer SYL3C to detect EpCAM expression in 170 cases of esophageal cancer (EC) and precancerous lesions, as well as 20 cases of EC series samples, using immunofluorescence imaging analysis. Corresponding antibodies were used as control. EpCAM overexpression was 98% in both esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EACA) and 100% in metastasis, but no EpCAM overexpression was detected in undifferentiated EC (UEC). Significant differences were noted among various stages of differentiation (p < 0.05) with the degree of differentiation inversely correlated with the expression of EpCAM. Overexpressed EpCAM was detected in severe dysplasia, but negative in mild to moderate dysplasia and benign esophageal lesions. In a competitive binding experiment, EpCAM aptamer generated a staining pattern similar to that of antibody, but the binding sites with EpCAM were different. Based on these results, it can be concluded that EpCAM is suitable for use as an EC biomarker, therapeutic target, and effective parameter for tumor transfer and prognosis evaluation by aptamer SYL3C staining.

Indexed as

AdenocarcinomaBiomarkers, TumorCarcinoma, Squamous CellEpithelial Cell Adhesion MoleculeEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaGene Expression Regulation, NeoplasticHumansLymphatic MetastasisNeoplasm StagingPrognosisSELEX Aptamer TechniqueBiomarkers, TumorEPCAM protein, humanEpithelial Cell Adhesion Molecule

Identifiers

PMID26687301
PMCPMC4685197
OpenAlexW2407971916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.